Barclays analyst Carter Gould reiterated an Overweight rating and $140.00 price target on Merck (NYSE: MRK)The analyst comments "RCUS (covered ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE